KIROMIC BIOPHARMA INC (KRBP) 0.2299 -0.01 (-4.29%)
0.2299 -0.01 (-4.29%)
US4976341051 - Common Stock
Fundamental Rating
Taking everything into account, KRBP scores 1 out of 10 in our fundamental rating. KRBP was compared to 637 industry peers in the Biotechnology industry. KRBP has a bad profitability rating. Also its financial health evaluation is rather negative. KRBP is valued expensive and it does not seem to be growing.
Profitability
Profitability Rating
KRBP has a Piotroski-F score of 4.00. This indicates an average health and profitability for KRBP.
The profitability ratios for KRBP are negative, so there is not much use analyzing them.
KRBP has a Return On Assets of -166.81%. This is below the industry average of -44.55%. 92% of the industry peers outperform KRBP.
VS Industry
ROA (-166.81%) VS Industry: 8% outperformed.
-3,944.82
115.38
Valuation
Valuation Rating
When comparing the current price to the book value of KRBP, it is valued rather cheaply. It is trading at 0.36 times its book value.
When comparing the price book ratio of KRBP to the average industry price book ratio of 1.69, KRBP is valued rather cheaply. KRBP is also cheaper than 90% of the companies listed in the same industry.
Compared to an average Enterprise Value to EBITDA ratio of 1.08, KRBP is valued rather cheaply. On top of this, KRBP has a better ratio than 95% of the companies listed in the same industry.
The Price/Earnings Ratio is negative for KRBP. In the last year negative earnings were reported.
Also next year KRBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry
Price/Book (0.36) VS Industry: 90% outperformed.
138.52
0.09
Enterprise Value/ EBITDA (0.06) VS Industry: 95% outperformed.
3,199.01
0.01
Growth
Growth Rating
KRBP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.52%.
The Earnings Per Share is expected to decrease by -0.75% on average over the next 5 years.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -3.52% | -8.04% | -9.13% | 0% | -0.75% |
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Health
Health Rating
A Current Ratio of 1.35 indicates that KRBP should not have too much problems paying its short term obligations.
A Quick Ratio of 1.35 indicates that KRBP should not have too much problems paying its short term obligations.
The Debt to Equity ratio of KRBP is in line with the industry averages.
KRBP has a Piotroski-F score of 4.00. This indicates an average health and profitability for KRBP.
Compared to an average industry Current Ratio of 6.11, KRBP is worse placed to pay its short term obligations than its industry peers. 91% of its industry peers have a better Current Ratio.
Compared to an average industry Quick Ratio of 6.02, KRBP is worse placed to pay its short term obligations than its industry peers. 90% of its industry peers have a better Quick Ratio.
KRBP has an Altman-Z score of -10.90. This is a bad value and indicates that KRBP is not financially healthy and even has some risk of bankruptcy.
When comparing the Altman-Z score of KRBP to the average industry Altman-Z score of -0.62, KRBP is less financially healthy than its industry peers. 84% of its industry peers have a better Altman-Z score.
VS Industry
Debt/Equity (0) VS Industry: 42% outperformed.
15.37
0.00
Quick Ratio (1.35) VS Industry: 10% outperformed.
0.02
84.53
Current Ratio (1.35) VS Industry: 9% outperformed.
0.02
85.09
Altman-Z (-10.9) VS Industry: 16% outperformed.
-1,822.12
441.73
Dividend
Dividend Rating
KRBP does not give a dividend.
KIROMIC BIOPHARMA INC0.2299
NASDAQ:KRBP (12/8/2022, 7:00:02 PM)-0.01 (-4.29%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 08-12 2022-08-12/amc | Earnings (Next) | 03-09 2023-03-09 |
| Ins Owners | 6.56% | Inst Owners | 1.68% |
| Market Cap | 4.19M | Analysts | N/A |
| PE | N/A | Fwd PE | N/A |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | N/A | P/B | 0.36 |
| EV/EBITDA | 0.06 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS 1Y | -3.52% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | 20.59% |
| EPS Next Y | -8.04% | EPS Next 2Y | -9.13% |
| EPS Next 3Y | 0% | EPS Next 5Y | -0.75% |
| Revenue growth 1Y | N/A | Revenue growth 3Y | N/A |
| Revenue growth 5Y | N/A | Revenue growth Q2Q | N/A |
| Revenue Next Year | N/A | Revenue Next 2Y | N/A |
| Revenue Next 3Y | N/A | Revenue Next 5Y | N/A |
| Current Ratio | 1.35 | Quick Ratio | 1.35 |
| Altman-Z | -10.9 | F-Score | 4 |
| Debt/Equity | 0 | WACC | N/A |
| ROIC/WACC | N/A | ||
| ROA | -166.81% | ROE | N/A |
| ROICexgc | N/A | ROIC | N/A |
| PM | N/A | OM | N/A |
| Asset Turnover | N/A | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA